Antacids, Gastrointestinal Prokinetics, and Proton Pump Inhibitors



Gastric acid acts as a major defense mechanism of the body by sterilizing the contents entering the digestive tract, prevents colonization of bacteria, and helps in digestion. Too much or too little acidic gastric acid is pathologic and can lead to many disorders including peptic ulcer disease, acid reflux, aspiration, pneumonias, and even cancer. Gastric acid secretion is a complex process, and the pharmacological agents which help decrease the pH and volume of gastric acid are antacids, H2 receptor antagonists, and proton pump inhibitors. Gastrointestinal prokinetics are class of drugs that improve small bowel motility and gastric emptying. We will review the pharmacology of antacids, prokinetics, and PPIs in this chapter.


Gastric Emptying Peptic Ulcer Disease Tardive Dyskinesia Erosive Esophagitis Eosinophilic Esophagitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material


  1. 1.
    Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med. 1988;319:1707–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Feldman M. Gastric secretion: normal and abnormal. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Gastrointestinal and liver disease. Philadelphia: Saunders; 1998. p. 587–603.Google Scholar
  3. 3.
    Zeng N, Athmann C, Kang T, et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest. 1999;104:1383–91.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Dubois A. Control of gastric acid secretion. In: Brandt LJ, editor. Clinical practice of gastroenterology. Philadelphia: Current Medicine; 1999. p. 180–8.Google Scholar
  5. 5.
    Fordtran JS, Collyns JAH. Antacid pharmacology in duodenal ulcer. Effect of antacids on postcibal gastric acidity and peptic activity. N Engl J Med. 1966;274:92–7.CrossRefGoogle Scholar
  6. 6.
    AHFS drug information. In: Mc Evoy GK, editor. Bethesda: American Society of Health-System Pharmacists; 1998. p. 2374–9.Google Scholar
  7. 7.
    Littman A, Pine BH. Antacid and anticholinergic drugs. Ann Intern Med. 1975;82:544–15.PubMedCrossRefGoogle Scholar
  8. 8.
    Mirrissey JF, Barreras RF. Antacid therapy. N Engl J Med. 1974;290:550–4.CrossRefGoogle Scholar
  9. 9.
    Harvey SC. Gastric antacids and digestants. In: Goodman LS, Gillian A, Gillian AG, editors. The pharmacological basis of therapeutics. 6th ed. New York: Macmillan; 1980. p. 988–1001.Google Scholar
  10. 10.
    American Society of Anesthesiologists Committee. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology. 2011;114(3):495–511.Google Scholar
  11. 11.
    James CF, Gibbs CP. Nonparticulate antacids. Anesth Analg. 1982;61(9):801.PubMedCrossRefGoogle Scholar
  12. 12.
    Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest. 2001;119:1222–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs. 1997;54:581–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitic. Dig Dis Sci. 1983;28:559–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Regan PT, Malagelada JR, DiMagno EP, et al. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med. 1977;297:854–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Cousar GD, Gadacz TR. Comparison of antacids on the binding of bile salts. Arch Surg. 1984;119:1018–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Clemens JD, Feinstein AR. Calcium carbonate and constipation: a historical review of medical mythopoeia. Gastroenterology. 1977;72:957–61.PubMedGoogle Scholar
  18. 18.
    Saunders D, Sillery J, Chapman R. Effect of calcium carbonate and aluminum hydroxide on human intestinal function. Dig Dis Sci. 1988;33:409–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Strom M. Antacid side-effects on bowel habits. Scand J Gastroenterol. 1982;75(Suppl):54–5.Google Scholar
  20. 20.
    Maton PN, Burton ME. Antacids revisited, a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57(6):855–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Tatro DS. Drug interaction facts. Facts and comparisons. 3rd ed. St Louis; 1992.Google Scholar
  22. 22.
    Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet. 1984;9:404–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet. 1977;2:269–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Hansten PD, Horn JR, Koda-Kimble MA, et al., editors. Principles of antacid interaction. In: Drug interaction & updates quarterly. Vancouver: Applied Therapeutics, Inc.; 1993. p 69–72.Google Scholar
  25. 25.
    Hansten PD, Horn JR, Koda-Kimble MA, et al., editors. Antacid drug interactions. In: Drug interaction & updates quarterly. Vancouver: Applied Therapeutics, Inc.; 1993. p 137–51.Google Scholar
  26. 26.
    Gugler AH. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet. 1990;18:210–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones. Drug Saf. 1995;12:314–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Herzog P, Holtermüller KH. Antacid therapy—changes in mineral metabolism. Scand J Gastroenterol Suppl. 1982;75:56–62. [0085-5928] Herzog.PubMedGoogle Scholar
  29. 29.
    McMillan DE, Freeman RB. The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition. Medicine. 1965;44:485–501.PubMedCrossRefGoogle Scholar
  30. 30.
    Merwat SN, Spechler SJ. Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol. 2009;104:1897–902.PubMedCrossRefGoogle Scholar
  31. 31.
    Canani RB, Terrin G. Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol. 2010;26:31–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341:137.PubMedCrossRefGoogle Scholar
  33. 33.
    Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000;43:599.PubMedCrossRefGoogle Scholar
  34. 34.
    Loftus CG, Harewood GC, Baron TH. Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction. Am J Gastroenterol. 2002;97:3118–22.PubMedCrossRefGoogle Scholar
  35. 35.
    Holte K, Kehlet H. Postoperative ileus: progress towards effective management. Drugs. 2002;62(18):2603–15.PubMedCrossRefGoogle Scholar
  36. 36.
    Hallerbäck B, Ander S, Glise H. Effect of combined blockade of beta-adrenoceptors and acetylcholinesterase in the treatment of postoperative ileus after cholecystectomy. Scand J Gastroenterol. 1987;22(4):420–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Maher L, Young PJ. Cardiac arrest complicating neostigmine use for bowel opening in a critically ill patient. Crit Care Resusc. 2011;13(3):192–3.PubMedGoogle Scholar
  38. 38.
    Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther. 1993;7:5–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med. 1983;98:86–95.PubMedCrossRefGoogle Scholar
  40. 40.
    McCallum RW. Clinical pharmacology forum: motility agents and the gastrointestinal tract. Am J Med Sci. 1996;312:19–26.PubMedCrossRefGoogle Scholar
  41. 41.
    Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc. 2004;44:661–5.CrossRefGoogle Scholar
  42. 42.
    McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet. 1983;8(6):523–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Walker M, Samii A. Chronic severe dystonia after single exposure to antiemetics. Am J Emerg Med. 2006;24:125–7.PubMedCrossRefGoogle Scholar
  45. 45.
    McCallum RW, Sowers JR, Hershman JM, Sturdevant RAL. Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab. 1976;42:1148–52.PubMedCrossRefGoogle Scholar
  46. 46.
    Edwards M, Koo MW, Tse RK. Oculogyric crisis after metoclopramide therapy. Optom Vis Sci. 1989;66:179–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Nonino F, Campomori A. Neuroleptic malignant syndrome associated with metoclopramide. Ann Pharmacother. 1999;33(5):644–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48:379–84.PubMedCrossRefGoogle Scholar
  50. 50.
    Reddymasu SC M.D., Soykan I M.D., McCallum RW M.D. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036–45.PubMedCrossRefGoogle Scholar
  51. 51.
    Reynolds JC. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin N Am. 1989;18:437–57.Google Scholar
  52. 52.
    Weber Jr FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastro intestinal prokinetic agent. Am J Gastroenterol. 1993;88(4):485–90.PubMedGoogle Scholar
  53. 53.
    Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;18:CD001960.Google Scholar
  54. 54.
    Karamanolis G, Tack J. Promotility medications—now and in the future. Dig Dis. 2006;24:297–307.PubMedCrossRefGoogle Scholar
  55. 55.
    Itoh Z. Motilin and clinical application. Peptides. 1997;18:593–608.PubMedCrossRefGoogle Scholar
  56. 56.
    Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil. 2005;17:643–53.PubMedCrossRefGoogle Scholar
  57. 57.
    Camilleri M, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18–37.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000;56:1–18.PubMedCrossRefGoogle Scholar
  59. 59.
    Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA. 1998;280:1774–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35:197–200.PubMedCrossRefGoogle Scholar
  61. 61.
    Berthet S, Charpiat B, Mabrut JY. Erythromycin as a prokinetic agent: risk factors. J Visceral Surg. 2010;147:e13–8.CrossRefGoogle Scholar
  62. 62.
    Thompson JS M.D., Quigley EMM M.D. Prokinetic agents in the surgical patient. Am J Surg (Omaha, NE). 1999;177:508–14.CrossRefGoogle Scholar
  63. 63.
    Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol. 2012;83(3):388–92.PubMedCrossRefGoogle Scholar
  64. 64.
    Owyang C. Octreotide in gastrointestinal motility disorders. Gut. 1994;35 Suppl 3:S11–4.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. NEJM. 1991;325:1461–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Gunshefski LA, Rifley WJ, Slattery DW, et al. Somatostatin stimulation of the normal esophagus. Am J Surg. 1992;163:59–62.PubMedCrossRefGoogle Scholar
  67. 67.
    Cullen JJ, Eagon C, Dozois EJ, Kelly KA. Treatment of acute postoperative ileus with octreotide. Am J Surg. 1993;165:113–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Waller SL. Prostaglandins and the gastrointestinal tract. Gut. 1973;14(5):402–17.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Soffer EE, Launspack J. Effect of misoprostol on postprandial intestinal motility and orocecal transit time in humans. Dig Dis Sci. 1993;18:851–5.CrossRefGoogle Scholar
  70. 70.
    Bassotti G, Bucaneve G, Furno P, et al. Double blind, placebo controlled study on the effects of diclofenac sodium and indomethacin on postprandial gastric motility in man. Dig Dis Sci. 1998;42:1172–6.CrossRefGoogle Scholar
  71. 71.
    Kapoor S. Lubiprostone: clinical applications beyond constipation. World J Gastroenterol. 2009;15(9):1147–7.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung EZ, Lee K, Sanger GJ. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol. 2008;154:126–35.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012;11(5):841–50.PubMedCrossRefGoogle Scholar
  74. 74.
    Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16 Suppl 2:17–28.PubMedCrossRefGoogle Scholar
  75. 75.
    Neyens R, Jackson KC. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. J Pain Palliat Care Pharmacother. 2007;21:27–33.PubMedCrossRefGoogle Scholar
  76. 76.
    Lambert R. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1997;11:651–62.PubMedCrossRefGoogle Scholar
  77. 77.
    Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:286–96.PubMedCrossRefGoogle Scholar
  78. 78.
    Lanza FL, Chan FK, Quigley EM, Practice parameters committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–38.PubMedCrossRefGoogle Scholar
  79. 79.
    Chubineh S M.D., Birk J M.D. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J. 2012;105(11):613–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger–Ellison syndrome. Expert Opin Pharmacother. 2009;10(7):1145–57.PubMedCrossRefGoogle Scholar
  81. 81.
    Neena S. Abraham, proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28:615–20.CrossRefGoogle Scholar
  82. 82.
    Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys. 2008;476:33–42.PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46:93–114.PubMedCrossRefGoogle Scholar
  84. 84.
    Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastro esophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4:50–4.PubMedCrossRefGoogle Scholar
  85. 85.
    Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118–22.PubMedCrossRefGoogle Scholar
  86. 86.
    Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.PubMedCrossRefGoogle Scholar
  88. 88.
    Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9:132–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545–53.PubMedCrossRefGoogle Scholar
  90. 90.
    Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Eng J Med. 2006;355:1834–6.CrossRefGoogle Scholar
  91. 91.
    Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009;151:755–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Dornebal J, Bijlsma R, Brouer RML. An unrecognized potential side effect of proton pump inhibitors: hypomagnesaemia. Ned Tidjschr Geenesk. 2009;153:A711.Google Scholar
  93. 93.
    Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors – a review. Neth J Med. 2009;67:169–72.PubMedGoogle Scholar
  94. 94.
    Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56:112–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Regolisti G, Cabassi A, Parenti E, et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010;56:168–74.PubMedCrossRefGoogle Scholar
  96. 96.
    Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010;103:387–95.PubMedCrossRefGoogle Scholar
  97. 97.
    Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a42.CrossRefGoogle Scholar
  98. 98.
    Administration US FDA. FDA Drug Safety Communication: low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). 2011.
  99. 99.
    Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256–60.PubMedCrossRefGoogle Scholar
  100. 100.
    Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52:1038–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713–8.PubMedCentralPubMedCrossRefGoogle Scholar
  102. 102.
    Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.PubMedCrossRefGoogle Scholar
  103. 103.
    Yeo C. Shackelford’s surgery of the alimentary tract. 6th ed. Philadelphia: WB Saunders; 2007.Google Scholar
  104. 104.
    Townsend CM. Sabiston textbook of surgery. 19th ed. Philadelphia: Saunders Elsevier; 2012.Google Scholar
  105. 105.
    Brenner GM. Pharmacology. 4th ed. Philadelphia: Saunders Elsevier; 2012.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Anesthesiology and Perioperative MedicineUniversity of Louisville School of MedicineLouisvilleUSA

Personalised recommendations